应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
02607 上海医药
休市中 01-03 16:08:08
12.540
-0.020
-0.16%
最高
12.680
最低
12.500
成交量
322.03万
今开
12.660
昨收
12.560
日振幅
1.43%
总市值
464.98亿
流通市值
115.24亿
总股本
37.08亿
成交额
4,043万
换手率
0.35%
流通股本
9.19亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
每日全球并购：上海医药拟收购获取上海和黄药业控制权 加密货币经纪公司FalconX收购衍生品初创公司Arbelos（1/3）
晨哨并购 · 01-03 22:30
每日全球并购：上海医药拟收购获取上海和黄药业控制权 加密货币经纪公司FalconX收购衍生品初创公司Arbelos（1/3）
上海医药斥资近10亿成为和黄药业实控人
国际金融报 · 01-03 16:34
上海医药斥资近10亿成为和黄药业实控人
李嘉诚又抛售资产，45亿元甩卖，上海医药成为实控人
谈医说药 · 01-03 16:23
李嘉诚又抛售资产，45亿元甩卖，上海医药成为实控人
上海医药最新公告：全资子公司上药第一生化的硝酸异山梨酯注射液通过仿制药一致性评价
证券之星 · 01-02 17:02
上海医药最新公告：全资子公司上药第一生化的硝酸异山梨酯注射液通过仿制药一致性评价
上海医药(601607.SH)：硝酸异山梨酯注射液通过仿制药一致性评价
智通财经 · 01-02 16:56
上海医药(601607.SH)：硝酸异山梨酯注射液通过仿制药一致性评价
【上海医药：硝酸异山梨酯注射液通过仿制药一致性评价】上海医药公告，全资子公司上药第一生化药业有限公司的硝酸异山梨酯注射液通过仿制药质量和疗效一致性评价。该药品主要用于不稳定性心绞痛等治疗，2023年医院采购金额为9.07亿元。通过评价有利于扩大市场份额，提升竞争力，但受政策、市场环境影响，销售存在不确定性。
金融界 · 01-02 16:54
【上海医药：硝酸异山梨酯注射液通过仿制药一致性评价】上海医药公告，全资子公司上药第一生化药业有限公司的硝酸异山梨酯注射液通过仿制药质量和疗效一致性评价。该药品主要用于不稳定性心绞痛等治疗，2023年医院采购金额为9.07亿元。通过评价有利于扩大市场份额，提升竞争力，但受政策、市场环境影响，销售存在不确定性。
上海医药拟斥资近10亿并表上海和黄药业，进一步发力重中药板块
金融投资报 · 01-02 15:17
上海医药拟斥资近10亿并表上海和黄药业，进一步发力重中药板块
国金证券：给予上海医药买入评级
证券之星 · 01-02 12:03
国金证券：给予上海医药买入评级
《股市简讯》香港和黄医药逆市劲扬逾一成，将出售中成药合资企业持股
路透中文 · 01-02 10:02
《股市简讯》香港和黄医药逆市劲扬逾一成，将出售中成药合资企业持股
【港股通】上海医药(02607)拟收购上海和黄10%股权 耗资9.95亿元人民币
金吾财讯 · 01-02 09:05
【港股通】上海医药(02607)拟收购上海和黄10%股权 耗资9.95亿元人民币
上海医药(02607.HK)斥约9.95亿人币购上海和黄药业10%股权
阿斯达克财经 · 01-02 08:27
上海医药(02607.HK)斥约9.95亿人币购上海和黄药业10%股权
21健讯Daily｜新版医保药品目录正式施行；上海医药拟收购和黄10%股权；汇宇制药董事长被罚
21世纪经济报道 · 01-02 07:45
21健讯Daily｜新版医保药品目录正式施行；上海医药拟收购和黄10%股权；汇宇制药董事长被罚
上海医药拟并表上海和黄药业 提升中药产品销售及国际化能力
证券日报 · 01-02 01:34
上海医药拟并表上海和黄药业 提升中药产品销售及国际化能力
上海医药拟9.95亿元收购上海和黄药业10%股权
每日经济新闻 · 01-02 00:15
上海医药拟9.95亿元收购上海和黄药业10%股权
上海医药终止三项美国临床试验项目，累计研发投入超8000万元
美港电讯 · 01-01 23:36
上海医药终止三项美国临床试验项目，累计研发投入超8000万元
上海医药终止三项美国临床试验项目，累计研发投入超8000万元
第一财经 · 01-01 22:40
上海医药终止三项美国临床试验项目，累计研发投入超8000万元
和黄医药再次剥离中药资产 上海医药拟斥资近10亿元实控和黄药业
第一财经 · 01-01 21:25
和黄医药再次剥离中药资产 上海医药拟斥资近10亿元实控和黄药业
上海医药与云南白药2025年日常/持续关连交易金额上限为19亿元
财中社 · 01-01 20:43
上海医药与云南白药2025年日常/持续关连交易金额上限为19亿元
上海医药最新公告：决定终止三个研发项目的临床试验及后续开发
证券之星 · 01-01
上海医药最新公告：决定终止三个研发项目的临床试验及后续开发
上海医药(02607)拟以9.95亿元收购上海和黄10%股权
智通财经 · 01-01
上海医药(02607)拟以9.95亿元收购上海和黄10%股权
加载更多
公司概况
公司名称：
上海医药
所属市场：
SEHK
上市日期：
--
主营业务：
上海医药集团股份有限公司是一家主要从事医药工业、分销与零售业务的中国公司。该公司的产品包括创新药、化学药、中药和罕见病药。该公司的产品主要用于心血管系统、消化道和新陈代谢、全身性抗感染、中枢神经系统、抗肿瘤和免疫调节剂、骨骼肌肉系统和呼吸系统等领域。另外，该公司还提供医药物流和仓储服务。该公司的产品销往中国国内和海外市场。
发行价格：
--
{"stockData":{"symbol":"02607","market":"HK","secType":"STK","nameCN":"上海医药","latestPrice":12.54,"timestamp":1735891688032,"preClose":12.56,"halted":0,"volume":3220300,"delay":0,"floatShares":919000000,"shares":3708000000,"eps":1.0759711517202217,"marketStatus":"休市中","change":-0.02,"latestTime":"01-03 16:08:08","open":12.66,"high":12.68,"low":12.5,"amount":40432515,"amplitude":0.014331,"askPrice":12.56,"askSize":19600,"bidPrice":12.54,"bidSize":600,"shortable":3,"etf":0,"ttmEps":1.1417825936184942,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1736127000000},"marketStatusCode":7,"adr":0,"listingDate":1305820800000,"exchange":"SEHK","adjPreClose":12.56,"dividendRate":0.044657,"openAndCloseTimeList":[[1735867800000,1735876800000],[1735880400000,1735891200000]],"volumeRatio":0.8683469925740352,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"601607","market":"SH","secType":"STK","nameCN":"上海医药","latestPrice":20.48,"timestamp":1735887600000,"preClose":20.6,"halted":0,"volume":9457500,"delay":0,"premium":"-42.07"}},"requestUrl":"/m/hq/s/02607","defaultTab":"news","newsList":[{"id":"2500112156","title":"每日全球并购：上海医药拟收购获取上海和黄药业控制权 加密货币经纪公司FalconX收购衍生品初创公司Arbelos（1/3）","url":"https://stock-news.laohu8.com/highlight/detail?id=2500112156","media":"晨哨并购","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500112156?lang=zh_cn&edition=full","pubTime":"2025-01-03 22:30","pubTimestamp":1735914600,"startTime":"0","endTime":"0","summary":"公司终止收购杭州睿新所持有太阳高新51%股份事宜。(格隆汇)3. 加密货币经纪公司FalconX收购衍生品初创公司Arbelos Markets数字资产主要经纪公司FalconX收购了Arbelos Markets，这是一家由两位加密货币行业资深人士于2023年创立的衍生品初创公司。上海医药拟联合上海金浦健服股权投资管理有限公司指定主体共同收购和黄医药持有的上海和黄药业股权。交易完成后，上海医药将合计持有上海和黄药业60%股权，对其实施并表。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-01-03/doc-inecthkt1358891.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BTCO","DOT.USD.HKCC","BK4585","APT.USD.CC","HODL","COMP.USD.HKCC","AVAX.USD.CC","EZBC","RNDR.USD.HKCC","601607","SNX.USD.HKCC","ATOM.USD.HKCC","MATIC.USD.CC","DOT.USD.CC","BK0175","APT.USD.HKCC","LTC.USD.HKCC","MATIC.USD.HKCC","BK0188","BK0012","BK4594","COMP.USD.CC","AVAX.USD.HKCC","BK0099","UNI.USD.CC","FBTC","BITO","LINK.USD.HKCC","BRRR","DEFI","BTCW","LDO.USD.HKCC","02607","BK0209","GBTC","UNI.USD.HKCC","TON.USD.HKCC","TON.USD.CC","BK1197","SNX.USD.CC","BK0184","MKR.USD.CC","BK0020","DYDX.USD.HKCC","BK0097","BK4601","BK0028","BK0183","USDT.USD.CC"],"gpt_icon":1},{"id":"2500169219","title":"上海医药斥资近10亿成为和黄药业实控人","url":"https://stock-news.laohu8.com/highlight/detail?id=2500169219","media":"国际金融报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500169219?lang=zh_cn&edition=full","pubTime":"2025-01-03 16:34","pubTimestamp":1735893289,"startTime":"0","endTime":"0","summary":"新年伊始，上海医药公布了几大重要事项。1月1日晚间，上海医药公告称，为了聚焦优势项目和和合理资源配置，公司决定终止在美国进行的三个研发项目的临床试验及后续开发，分别是I001-B（美国）、I022（美国）、C012（美国）这三个研发项目。1月2日，上海医药再次公告，拟收购上海和黄药业有限公司10%股权暨成为实际控制人。上述研发项目累计投入8068.65万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202501033287128020.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202501033287128020.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1197","02607"],"gpt_icon":0},{"id":"2500381161","title":"李嘉诚又抛售资产，45亿元甩卖，上海医药成为实控人","url":"https://stock-news.laohu8.com/highlight/detail?id=2500381161","media":"谈医说药","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500381161?lang=zh_cn&edition=full","pubTime":"2025-01-03 16:23","pubTimestamp":1735892610,"startTime":"0","endTime":"0","summary":"李家又抛售资产了，这次是医药。1月1月，上海医药、和黄医药先后发布公告，宣布达成股权收购协议。此次交易完成后，上海医药将合计持有上海和黄药业 60% 股权，对其实施并表。公告显示，上海和黄药业 2023 年度及 2024 年 1-9 月实现净利润分别为 6.63 亿元及 5.73 亿元，占上海医药同期净利润的比率分别为 12.84% 及 11.4%。这次抛售医药资产，着实出乎很多人意外。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250103162813a213fdb6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250103162813a213fdb6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1197","BK1500","BK1191","00001","00013","BK1601","BK1587","IE0032431581.USD","LU0072462343.USD","LU1571399168.USD","02607","BK1230","BK1521","BK1588","LU1048588211.SGD","BK1569"],"gpt_icon":0},{"id":"2500667917","title":"上海医药最新公告：全资子公司上药第一生化的硝酸异山梨酯注射液通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2500667917","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500667917?lang=zh_cn&edition=full","pubTime":"2025-01-02 17:02","pubTimestamp":1735808529,"startTime":"0","endTime":"0","summary":"上海医药公告，全资子公司上药第一生化收到国家药监局颁发的关于硝酸异山梨酯注射液的《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。该药品主要用于不稳定性心绞痛的对症治疗，血管痉挛性心绞痛的长期治疗，急性心肌梗死，急性左心衰竭等。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025010200022758.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","BK0028","02607","BK0196","BK0184","BK0012","BK0175","BK0209","BK0183","BK0099","BK1197","BK0097","601607","BK0188","BK0187"],"gpt_icon":0},{"id":"2500912789","title":"上海医药(601607.SH)：硝酸异山梨酯注射液通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2500912789","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500912789?lang=zh_cn&edition=full","pubTime":"2025-01-02 16:56","pubTimestamp":1735808211,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药 发布公告，近日，公司全资子公司上海上药第一生化药业有限公司收到国家药品监督管理局颁发的关于硝酸异山梨酯注射液的《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。2023年11月，上药第一生化就该药品仿制药一致性评价向国家药监局提出申请并获受理。截至公告日，公司针对该药品的一致性评价已投入研发费用约人民币530万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1232488.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0187","BK0196","BK0184","601607","BK0209","BK0188","BK0183","BK0012","BK1197","02607","BK0099","BK0028","BK0097","BK0175","BK0020"],"gpt_icon":0},{"id":"2500905912","title":"【上海医药：硝酸异山梨酯注射液通过仿制药一致性评价】上海医药公告，全资子公司上药第一生化药业有限公司的硝酸异山梨酯注射液通过仿制药质量和疗效一致性评价。该药品主要用于不稳定性心绞痛等治疗，2023年医院采购金额为9.07亿元。通过评价有利于扩大市场份额，提升竞争力，但受政策、市场环境影响，销售存在不确定性。","url":"https://stock-news.laohu8.com/highlight/detail?id=2500905912","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500905912?lang=zh_cn&edition=full","pubTime":"2025-01-02 16:54","pubTimestamp":1735808054,"startTime":"0","endTime":"0","summary":"上海医药公告，全资子公司上药第一生化药业有限公司的硝酸异山梨酯注射液通过仿制药质量和疗效一致性评价。该药品主要用于不稳定性心绞痛等治疗，2023年医院采购金额为9.07亿元。通过评价有利于扩大市场份额，提升竞争力，但受政策、市场环境影响，销售存在不确定性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/02165447039981.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0188","BK0184","BK0012","BK1197","BK0099","BK0183","BK0196","BK0028","BK0097","BK0187","BK0020","BK0209","02607","BK0175","601607"],"gpt_icon":0},{"id":"2500858915","title":"上海医药拟斥资近10亿并表上海和黄药业，进一步发力重中药板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2500858915","media":"金融投资报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500858915?lang=zh_cn&edition=full","pubTime":"2025-01-02 15:17","pubTimestamp":1735802239,"startTime":"0","endTime":"0","summary":"2025年1月1日晚间，上海医药(601607)公告称，公司拟联合上海金浦健服股权投资管理有限公司指定主体，共同收购上海和黄医药投资(香港)有限公司(下称和黄医药)持有的上海和黄药业有限公司(下称上海和黄药业)股权。2024年12月31日，上海医药与和黄医药签订股份转让协议，约定上海医药以人民币99503.66万元收购标的公司10%股权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202501023285462112.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1197","02607"],"gpt_icon":0},{"id":"2500995996","title":"国金证券：给予上海医药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2500995996","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500995996?lang=zh_cn&edition=full","pubTime":"2025-01-02 12:03","pubTimestamp":1735790601,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司赵海春,袁维近期对上海医药进行研究并发布了研究报告《拟控股上海和黄药业，中药板块再夯实》，本报告对上海医药给出买入评级，当前股价为20.88元。交易完成后，上海医药将合计持有上海和黄药业60%股权，对其实施并表。维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有11家机构给出评级，买入评级10家，增持评级1家；过去90天内机构目标均价为24.03。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025010200012292.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02607","601607"],"gpt_icon":0},{"id":"2500618709","title":"《股市简讯》香港和黄医药逆市劲扬逾一成，将出售中成药合资企业持股","url":"https://stock-news.laohu8.com/highlight/detail?id=2500618709","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500618709?lang=zh_cn&edition=full","pubTime":"2025-01-02 10:02","pubTimestamp":1735783369,"startTime":"0","endTime":"0","summary":"《股市简讯》香港和黄医药逆市劲扬逾一成，将出售中成药合资企业持股* 香港首富李嘉诚旗下的和黄医药0013.HK周四早盘高开3.1%，随后涨幅扩大至11.8%。* 该公司上日公告称，拟出售中成药合资企业--上海和黄药业45%的股权，仅保留5%间接股权，以将资源集中在其核心业务领域。* 上海和黄药业的核心产品是用于治疗心绞痛的中成药“麝香保心丸”及用于治疗胆石症的中成药“胆宁片”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250102:nL4T3NY02E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0969580561.USD","LU0557290698.USD","BK0196","603289","LU2324357040.USD","LU1496350502.SGD","BK1197","LU0738911758.USD","SG9999001176.USD","IE00BJT1NW94.SGD","LU0757432116.USD","LU2089984988.USD","02607","LU1019632923.USD","LU1153584641.USD","IE0009355771.USD","LU2112291526.USD","LU1051770623.HKD","SG9999001176.SGD","LU0972486137.USD","LU0011850046.USD","LU0052756011.USD","LU0823416689.USD","LU1291159041.SGD","LU0708994859.HKD","SGXZ57979304.SGD","BK0175","LU0553294199.USD","BK0188","LU0310800379.SGD","LU1261432733.SGD","BK0012","BK0099","LU0128525929.USD","LU1057294990.SGD","LU0997586432.USD","LU0158827948.USD","LU0211326839.USD","LU1481600234.SGD","AZN.UK","LU0310799852.SGD","03165","00013","LU2133065610.SGD","LU1481599808.USD","LU1983299246.USD","LU2023251221.USD","LU0882574055.USD","601607","IE0002141913.USD"],"gpt_icon":0},{"id":"2500653159","title":"【港股通】上海医药(02607)拟收购上海和黄10%股权 耗资9.95亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2500653159","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500653159?lang=zh_cn&edition=full","pubTime":"2025-01-02 09:05","pubTimestamp":1735779925,"startTime":"0","endTime":"0","summary":"金吾财讯 | 上海医药(02607)宣布，同意收购上海和黄(目标公司)10%股权，代价为9.95亿元人民币。同日，金浦健服（公司独立第三方）与和黄投资订立股份转让协议，据此金浦健服或其指定主体将收购而和黄投资同意出售上海和黄35%股权。上海和黄分别由和黄投资及该公司全资附属公司上药药材持有50%及50%股权。于收购事项完成后，上海和黄将由该公司直接及间接持有60%股权，并将成为该公司的非全资附属公司。目标公司一直围绕物质基础、作用机理，再到临床疗效循证，不断探索中医药现代化、国际化的可能性和路径。核心产品包括麝香保心丸、胆宁片，生产基地位于上海奉贤。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/ZmY0OWUwYjc0ZDYzZDFkYzRkNWJlMTY3NjE5MjUxNjU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZmY0OWUwYjc0ZDYzZDFkYzRkNWJlMTY3NjE5MjUxNjU=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1950563","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0099","HSTECH","BK0196","HSCEI","BK1197","BK0097","BK0188","YANG","BK0209","BK0184","BK0175","02607","BK0020","BK0187","BK0012","BK0028","07226","BK0183","601607"],"gpt_icon":0},{"id":"2500968294","title":"上海医药(02607.HK)斥约9.95亿人币购上海和黄药业10%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2500968294","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500968294?lang=zh_cn&edition=full","pubTime":"2025-01-02 08:27","pubTimestamp":1735777620,"startTime":"0","endTime":"0","summary":"上海医药公布，去年12月31日与和黄投资订立股份转让协议。据悉，上海医药同意向和黄投资收购“上海和黄药业”10%股权，代价约9.95亿元人民币。截至昨日，上海和黄药业由和黄投资及上海医药全资附属公司上药药材分别持有50%股权。于收购事项完成后，“上海和黄药业”将由上海医药直接及间接持有60%股权，并将成为该公司的非全资附属公司，且其财务业绩将综合计入集团综合财务报表内。(港股报价延迟最少十五分钟。沽空资料截至 2024-12-31 12:25。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190401142438853_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190401142438853_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1407255/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0188","BK0184","BK0012","BK1197","BK0099","BK0183","BK0196","BK0028","BK0097","BK0187","BK0020","BK0209","02607","BK0175","601607"],"gpt_icon":0},{"id":"2500982957","title":"21健讯Daily｜新版医保药品目录正式施行；上海医药拟收购和黄10%股权；汇宇制药董事长被罚","url":"https://stock-news.laohu8.com/highlight/detail?id=2500982957","media":"21世纪经济报道","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500982957?lang=zh_cn&edition=full","pubTime":"2025-01-02 07:45","pubTimestamp":1735775150,"startTime":"0","endTime":"0","summary":"政策动向第三批中成药集采开标2024年12月30日，第三批全国中成药采购联盟集采在湖北武汉开标，同日深夜拟中选结果公示。前两批相比，第三批中成药集采范围进一步扩大，所涉剂型也从之前的口服中成药为主扩展至口服及较多的注射剂，纳入了双黄连注射液、清开灵注射液等市场大品种，共涉及20个产品组。最终，共有175个品种拟中选，涉及厂家157家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202501023284675712.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202501023284675712.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02607","BK1197"],"gpt_icon":0},{"id":"2500934655","title":"上海医药拟并表上海和黄药业 提升中药产品销售及国际化能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2500934655","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500934655?lang=zh_cn&edition=full","pubTime":"2025-01-02 01:34","pubTimestamp":1735752876,"startTime":"0","endTime":"0","summary":"1月1日晚间，上海医药集团股份有限公司（以下简称“上海医药”）发布公告称，公司拟联合上海金浦健服股权投资管理有限公司指定主体共同收购上海和黄医药投资（香港）有限公司（以下简称“和黄医药”）持有的上海和黄药业有限公司（以下简称“上海和黄药业”）股权。其中，上海医药已与和黄医药签订股份转让协议，拟以9.95亿元收购上海和黄药业10%股权（以最终国资备案价格为准）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202501023284652895.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1197","02607"],"gpt_icon":0},{"id":"2500693640","title":"上海医药拟9.95亿元收购上海和黄药业10%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2500693640","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500693640?lang=zh_cn&edition=full","pubTime":"2025-01-02 00:15","pubTimestamp":1735748118,"startTime":"0","endTime":"0","summary":"1月1日晚间，上海医药（SH601607，股价21.00元，市值778.61亿元）公告称，公司拟联合上海金浦健服股权投资管理有限公司指定主体共同收购上海和黄医药投资(香港)有限公司（以下简称“和黄医药”）持有的上海和黄药业有限公司（以下简称“上海和黄药业”）股权，其中上海医药拟以9.95亿元收购10%股权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202501023284648124.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202501023284648124.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02607","BK1197"],"gpt_icon":0},{"id":"2500933287","title":"上海医药终止三项美国临床试验项目，累计研发投入超8000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2500933287","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500933287?lang=zh_cn&edition=full","pubTime":"2025-01-01 23:36","pubTimestamp":1735745761,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0196","03347","BK0209","BK0099","BK1141","BK0183","BK0028","BK0175","BK0187","BK0184","BK1576","BK0188","BK1583","BK0012","BK0097","BK0020","601607","02607","BK1197"],"gpt_icon":0},{"id":"2500938624","title":"上海医药终止三项美国临床试验项目，累计研发投入超8000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2500938624","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500938624?lang=zh_cn&edition=full","pubTime":"2025-01-01 22:40","pubTimestamp":1735742405,"startTime":"0","endTime":"0","summary":"上海医药（601607.SH）对于研发项目的调整仍在持续。2025年1月1日晚间，公司公告称，决定终止I001-B（美国）、I022（美国）、C012（美国）这三个研发项目的临床试验及后续开发。其中，I001-B（美国）及I022（美国）处于美国临床试验II期，C012（美国）获得美国食品药品监督管理局（以下简称“FDA”）I期临床试验许可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202501013284624548.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202501013284624548.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1576","BK1197","02607","BK1141","03347"],"gpt_icon":0},{"id":"2500982273","title":"和黄医药再次剥离中药资产 上海医药拟斥资近10亿元实控和黄药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2500982273","media":"第一财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500982273?lang=zh_cn&edition=full","pubTime":"2025-01-01 21:25","pubTimestamp":1735737900,"startTime":"0","endTime":"0","summary":"交易完成后，上海医药将合计持有上海和黄药业60%股权，成为和黄药业的实际控制人。上海医药拟以自有资金人民币9.95亿元收购上海和黄药业的10%股权，交易完成后，上海医药股权比例增至60%，并对上海和黄药业实施并表。和黄医药进一步剥离中医药资产对于和黄医药来说，当下的核心业务主要聚焦在肿瘤和免疫领域的创新药研发。此次出售上海和黄药业45%的股权，是其近年来剥离中药资产的动作延续。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501012129039857af03&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501012129039857af03&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","00013","BK1588","02607","BK1197","BK1191"],"gpt_icon":0},{"id":"2500984768","title":"上海医药与云南白药2025年日常/持续关连交易金额上限为19亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2500984768","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500984768?lang=zh_cn&edition=full","pubTime":"2025-01-01 20:43","pubTimestamp":1735735394,"startTime":"0","endTime":"0","summary":"财中社1月1日电上海医药（601607/02607）发布关于与云南白药集团股份有限公司续签《日常关联交易/持续关连交易框架协议》的公告。根据协议，2025年1月1日至2025年12月31日，公司向云南白药销售产品金额上限为12亿元，向云南白药采购产品金额上限为7亿元。云南白药持有公司17.95%的股份，属于公司关联方。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202501013284591567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02607","BK1197"],"gpt_icon":0},{"id":"2500398583","title":"上海医药最新公告：决定终止三个研发项目的临床试验及后续开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2500398583","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500398583?lang=zh_cn&edition=full","pubTime":"2025-01-01 19:00","pubTimestamp":1735729222,"startTime":"0","endTime":"0","summary":"上海医药公告，基于对研发项目未来市场价值、业务协同以及后续开发投入等因素的综合评估，决定终止I001-B（美国）、I022（美国）、C012（美国）这三个研发项目的临床试验及后续开发。其中，I001-B（美国）及I022（美国）处于美国临床试验II期，C012（美国）获得FDA I期临床试验许可。公司表示，本次终止临床试验及后续开发事项，不会对公司业绩产生重大影响。公司将继续重视药品研发，并严格控制研发成本，但新药研发风险高、周期长，存在诸多不确定性。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025010100007522.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","BK1141","BK0175","BK0184","BK0183","BK0097","601607","BK0028","02607","03347","BK0012","BK0188","BK0196","BK1583","BK1576","BK0020","BK1197","BK0187","BK0099"],"gpt_icon":0},{"id":"2500988893","title":"上海医药(02607)拟以9.95亿元收购上海和黄10%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2500988893","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500988893?lang=zh_cn&edition=full","pubTime":"2025-01-01 18:20","pubTimestamp":1735726825,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药 发布公告，于2024年12月31日，公司(买方)与和黄投资(卖方)订立股份转让协议，据此公司同意收购而和黄投资同意出售上海和黄10%股权，代价为人民币9.95亿元。同日，金浦健服与和黄投资订立股份转让协议，据此金浦健服或其指定主体将收购而和黄投资同意出售上海和黄35%股权。目标公司循证医学研究与学术推广的成功经验，将助力集团其他中药品种的开发和推广，同时进一步拓展零售及下沉市场覆盖。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1232149.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0099","BK1197","BK0196","BK0184","BK0183","BK0012","BK0209","BK0020","601607","BK0187","BK0188","02607","BK0028","BK0175","BK0097"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.shaphar.com.cn","stockEarnings":[{"period":"1week","weight":-0.0218},{"period":"1month","weight":-0.05},{"period":"3month","weight":-0.1106},{"period":"6month","weight":0.0756},{"period":"1year","weight":0.0756},{"period":"ytd","weight":-0.0063}],"compareEarnings":[{"period":"1week","weight":-0.0164},{"period":"1month","weight":0.0009},{"period":"3month","weight":-0.1309},{"period":"6month","weight":0.1102},{"period":"1year","weight":0.1871},{"period":"ytd","weight":-0.0149}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海医药集团股份有限公司是一家主要从事医药工业、分销与零售业务的中国公司。该公司的产品包括创新药、化学药、中药和罕见病药。该公司的产品主要用于心血管系统、消化道和新陈代谢、全身性抗感染、中枢神经系统、抗肿瘤和免疫调节剂、骨骼肌肉系统和呼吸系统等领域。另外，该公司还提供医药物流和仓储服务。该公司的产品销往中国国内和海外市场。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.004008},{"month":2,"riseRate":0.615385,"avgChangeRate":0.022499},{"month":3,"riseRate":0.615385,"avgChangeRate":0.015455},{"month":4,"riseRate":0.538462,"avgChangeRate":0.003331},{"month":5,"riseRate":0.538462,"avgChangeRate":-0.00636},{"month":6,"riseRate":0.5,"avgChangeRate":-0.012586},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.020804},{"month":8,"riseRate":0.428571,"avgChangeRate":0.005824},{"month":9,"riseRate":0.357143,"avgChangeRate":0.015401},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.020412},{"month":11,"riseRate":0.428571,"avgChangeRate":0.031213},{"month":12,"riseRate":0.571429,"avgChangeRate":-0.011642}],"exchange":"SEHK","name":"上海医药","nameEN":"SH PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海医药(02607)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海医药(02607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海医药,02607,上海医药股票,上海医药股票老虎,上海医药股票老虎国际,上海医药行情,上海医药股票行情,上海医药股价,上海医药股市,上海医药股票价格,上海医药股票交易,上海医药股票购买,上海医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海医药(02607)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海医药(02607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}